Rallybio Corporation
NASDAQ:RLYB · NASDAQ Capital Market
+$0.01 today
Vol 0.02M · Avg 0.25M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$9.0M +84.5% | -$57.8M +22.5% | -$74.6M -11.9% | -$66.7M -41.8% | -$47.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $92.0K -29.8% | $131.0K -12.7% | $150.0K -10.2% | $167.0K +53.2% | $109.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $5.3M -33.5% | $8.0M -26.8% | $10.9M +15.0% | $9.5M +160.6% | $3.6M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$4.2M -1524.8% | -$258.0K -106.0% | $4.3M +556.9% | -$936.0K +75.2% | -$3.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$152.0K +78.2% | -$698.0K -605.1% | -$99.0K -120.3% | $487.0K +149.9% | -$976.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$4.0M -1018.2% | $440.0K -89.9% | $4.4M +407.5% | -$1.4M +49.2% | -$2.8M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$22.0M -3616.6% | $627.0K +159.8% | -$1.0M -263.8% | $640.0K -57.5% | $1.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$29.8M +39.5% | -$49.3M +18.2% | -$60.3M -5.2% | -$57.3M -25.8% | -$45.5M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 | $0 +100.0% | -$12.0K +77.8% | -$54.0K +83.8% | -$333.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 +100.0% | -$2.0M +11.1% | -$2.3M -650.0% | -$300.0K +85.0% | -$2.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$17.7M +63.8% | -$48.9M +55.8% | -$110.7M +45.0% | -$201.3M -9965.8% | -$2.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $46.5M -45.0% | $84.4M -39.0% | $138.3M +54.6% | $89.5M +4370.5% | $2.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $18.5M | $0 -100.0% | $2.3M | $0 +100.0% | -$2.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $47.3M +41.1% | $33.5M +21.1% | $27.7M +124.7% | -$112.2M -4708.0% | -$2.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $16.0K -99.7% | $5.4M +3679.7% | $143.0K -99.7% | $51.5M -40.2% | $86.2M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 +100.0% | -$206.0K | $0 +100.0% | -$455.0K +85.9% | -$3.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $16.0K -99.7% | $5.2M +3535.7% | $143.0K -99.7% | $51.1M -38.4% | $83.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $17.5M +265.0% | -$10.6M +67.4% | -$32.5M +72.6% | -$118.4M -437.2% | $35.1M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$29.8M +39.5% | -$49.3M +18.2% | -$60.3M -5.1% | -$57.3M -25.0% | -$45.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$156.64M
Boundless Bio, Inc.
BOLD
$31.90M
iBio, Inc.
IBIO
$25.97M
Klotho Neurosciences, Inc.
KLTO
$20.08M
Exicure, Inc.
XCUR
$15.81M
TAO Synergies Inc.
TAOX
$12.09M
Cadrenal Therapeutics, Inc. Common Stock
CVKD
$9.39M
Sonnet BioTherapeutics Holdings, Inc.
SONN
$8.43M
Intensity Therapeutics, Inc.
INTS
$7.17M
Iterum Therapeutics plc
ITRM
$1.60M
SEC Filings
Recent regulatory filings
No filings found.
Does RLYB generate free cash flow?
Rallybio Corporation (RLYB) generated -$29,813,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does RLYB produce?
Operating cash flow was -$29,813,000.00, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.